Market Overview

Urticaria| A Drug Pipeline Analysis Report 2018| Technavio


Technavio has announced their latest drug pipeline analysis report on urticaria.
The report includes a detailed analysis of the pipeline molecules under
investigation within the defined data collection period to treat

This press release features multimedia. View the full release here:

Technavio has published a new report on the drug development pipeline for urticaria, including a det ...

Technavio has published a new report on the drug development pipeline for urticaria, including a detailed study of the pipeline molecules. (Graphic: Business Wire)

This report by Technavio
presents a detailed analysis of the market, including regulatory
framework, drug development strategies, recruitment strategies, and key
companies that are expected to play an essential role in the growth of
the market in the future.

This report is available at a USD 1,000 discount for a limited time
market snapshot before purchasing

Urticaria: Market overview

Urticaria is a skin disorder, which is popularly termed as hives. It is
a type of skin rash with red and itchy bumps. These rashes may cover an
area of a few millimeters to several centimeters. They mostly last for a
few days and do not leave any skin changes. The most common hives
causing foods are nuts, chocolates, fish, tomatoes, eggs, fresh berries,
and milk.

According to a senior market research analyst at Technavio, "Urticaria
frequently occurs following an infection or an allergic reaction due to
medication, insect bites, or food. It can also be triggered due to
psychological stress, cold temperature, or vibration. It lasts for short
duration and occurs equally in males and females; however, the long
duration cases are common in females. Based on the duration and type,
urticaria is subdivided into chronic urticaria, acute urticaria, chronic
spontaneous urticaria, cold contact urticaria, chronic idiopathic
urticaria, and chronic-antihistamine refractory urticaria."

Urticaria: Segmentation analysis

This pipeline analysis report segments the urticaria market based on
therapies employed (monotherapy), RoA (oral, subcutaneous, intravenous,
and topical), therapeutic modality (monoclonal antibody, small molecule,
and fusion protein), targets (IgE antibody, Bruton's tyrosine kinase
(BTK), siglec-8 receptor, histamine, interleukin 1 (IL-1), humanized
IL-5, spleen tyrosine kinase,histidine decarboxylase, and H1 receptor),
MoA (anti-IgE antibody, BTK inhibitor, siglec-8 receptor antagonist,
histamine H1 antagonist, humanized IL-5 antagonist, IL-1 inhibitor,
spleen tyrosine kinase inhibitor, irreversible histidine decarboxylase
inhibitor, and H1 receptor antagonist), geographical segmentation
(Americas, EMEA, and APAC) and recruitment status (active, not
recruiting, completed, not yet recruiting, and recruiting). It provides
an in-depth analysis of the prominent factors influencing the market,
including drivers, opportunities, trends, and industry-specific

Based on RoA, more than 31% of the molecules that are being investigated
for the treatment of urticaria are subcutaneous medication.

Looking for more information on this market? Request
a free sample report

Technavio's sample reports are free of charge and contain multiple
sections of the report such as the market size and forecast, drivers,
challenges, trends, and more.

Some of the key topics covered in the report include:

Scope of the Report

Regulatory Framework

Drug Development Landscape

  • Drugs under development
  • Indications coverage

Drug Development Strategies

  • Therapies employed
  • RoA
  • Therapeutic modality
  • Geographical coverage

Recruitment Strategies

  • Recruitment status
  • Gender
  • Age

Key Companies

  • Type of players
  • Company overview

Discontinued or Dormant Molecules

About Technavio

is a leading global technology research and advisory company. Their
research and analysis focuses on emerging market trends and provides
actionable insights to help businesses identify market opportunities and
develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists
of more than 10,000 reports and counting, covering 800 technologies,
spanning across 50 countries. Their client base consists of enterprises
of all sizes, including more than 100 Fortune 500 companies. This
growing client base relies on Technavio's comprehensive coverage,
extensive research, and actionable market insights to identify
opportunities in existing and potential markets and assess their
competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team

View Comments and Join the Discussion!